Literature DB >> 3742492

Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen.

L Kaplan, D Abrams, P Volberding.   

Abstract

Twenty-four patients with acquired immunodeficiency syndrome and Kaposi's sarcoma (KS) were treated with a regimen alternating vincristine with vinblastine on a weekly basis. Objective responses to this regimen were observed in nine patients (45%), and seven (35%) had stabilization of progressive KS. Few toxic effects were observed. Alternating vincristine-vinblastine therapy is well-tolerated and effective palliative treatment for KS in acquired immunodeficiency syndrome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3742492

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

Review 1.  AIDS and the lung. 7. Treatment of lung disease in patients with the acquired immune deficiency syndrome.

Authors:  D M Mitchell; M A Johnson
Journal:  Thorax       Date:  1990-03       Impact factor: 9.139

Review 2.  Drug treatment of HIV-related opportunistic infections.

Authors:  M E Klepser; T B Klepser
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Stabilization of vinca alkaloids encapsulated in poly(lactide-co-glycolide) microspheres.

Authors:  J Marinina; A Shenderova; S R Mallery; S P Schwendeman
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

Review 4.  A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma.

Authors:  G Nasti; D Errante; S Santarossa; E Vaccher; U Tirelli
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

5.  Diagnosis and Treatment of Kaposi's Sarcoma.

Authors:  Muhammad Wasif Saif
Journal:  Resid Staff Physician       Date:  2001-11

Review 6.  Treatment of Kaposi's sarcoma. Current guidelines and future perspectives.

Authors:  D W Northfelt
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

7.  Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.

Authors:  F D Goebel; D Goldstein; M Goos; H Jablonowski; J S Stewart
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.